Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.70 |
| ▸ | HTR1A | P08908 | 4/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | HRH1 | P35367 | 4/20 | 0.70 |
| ▸ | DRD3 | P35462 | 4/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.70 |
| ▸ | TP53 | P04637 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19786054 | 0.94 | DRD2 (0.65) | DRD2LMNACYP1A2HTR1ACYP2D6 | |
| SCHEMBL19196333 | 0.86 | SIGMAR1 (0.74) | DRD2LMNACYP1A2HTR1ACYP2D6 | |
| Chlorproethazine SCHEMBL29818123 | 0.85 | CYP1A2 (0.77) | DRD2LMNACYP1A2HTR1ACYP2D6 | |
| Chlorproethazine SCHEMBL149201 | 0.85 | CYP1A2 (0.77) | DRD2LMNACYP1A2HTR1ACYP2D6 | |
| Chlorproethazine SCHEMBL9724486 | 0.84 | LMNA (0.78) | DRD2LMNACYP1A2HTR1ACYP2D6 | |
| Chlorproethazine SCHEMBL1648952 | 0.83 | CYP1A2 (0.74) | DRD2LMNACYP1A2HTR1ACYP2D6 | |
| SCHEMBL5880420 | 0.83 | ITGB2 (0.73) | DRD2LMNACYP1A2HTR1ACYP2D6 | |
| Chlorpromazine SCHEMBL8321 | 0.83 | CYP1A2 (1.00) | DRD2LMNACYP1A2HTR1ACYP2D6 | |
| Chlorpromazine SCHEMBL29367385 | 0.83 | CYP1A2 (1.00) | DRD2LMNACYP1A2HTR1ACYP2D6 | |
| Chlorpromazine SCHEMBL29358018 | 0.83 | CYP1A2 (1.00) | DRD2LMNACYP1A2HTR1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008420-A1 | CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-13 | — | — | US | disclosed |
| US-10980808-B2 | Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190314374-A1 | CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| WO-2018013761-A1 | CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314374-A1 | CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | RPS6KA1, RPS6KA2, RPS6KA6 | DRD2 3333/4885LMNA 1761/4885CYP1A2 4640/4885 |
| US-20220008420-A1 | CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | RPS6KA1, RPS6KA2, RPS6KA6 | DRD2 3333/4885LMNA 1761/4885CYP1A2 4640/4885 |
| US-10980808-B2 | Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies | RPS6KA1, RPS6KA2, RPS6KA6 | DRD2 3333/4885LMNA 1761/4885CYP1A2 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.